ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country

SAN DIEGO—(BUSINESS WIRE)—Apr. 11, 2019—ACADIAPharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced support of several educational events for theParkinson’s disease community and their caregivers. ACADIA is committedto supporting the Parkinson’s community and increasing awareness aboutParkinson’s disease (PD) and Parkinson’s disease psychosis (PDP), aprogressive and debilitating non-motor condition characterized byhallucinations and delusions related to PD.

“We are driven to improve the lives of people with Parkinson’s diseasepsychosis and their caregivers,” said Steve Davis, ACADIA’s ChiefExecutive Officer. “This April, in honor of Parkinson’s Awareness Monthand World Parkinson’s Day, we encourage patients and their families toattend an event, which includes important resources to help themnavigate their unique journey with Parkinson’s. We are collaborating andpledging our support to Parkinson’s patient advocacy organizationsacross the country to help make educational events possible year-roundbecause we understand how critical this support and engagement can befor patients and their caregivers.”

In addition to continued support for the Michael J. Fox Foundation(MJFF) Parkinson’sDisease Education Consortium, an alliance between MJFF and industrypartners committed to patient and caregiver knowledge through educationprograms, ACADIA is sponsoring several events and activities thisParkinson’s Awareness Month, including:

• MovingDay^® walks hosted by Parkinson’s Foundation across thecountry give people with Parkinson’s and their families theopportunity to amplify their voice and raise money to increaseawareness and understanding of Parkinson’s disease.
• OptimismWalks hosted by the American Parkinson’s Disease Associationacross the country aim to turn the Parkinson’s community’s passion andconcern about Parkinson’s into a positive experience that raisesawareness of the disease.
• DavisPhinney Foundation for Parkinson’s Victory Summit^® inAustin on April 13 is a national education and inspiration event,offering in-person and virtual access to dynamic presentations fromleading movement disorder neurologists and therapists from across thecountry.
• Parkinson’sFoundation Centers for Excellence Leadership Conference hosted 45Parkinson’s centers to discuss in-network updates, cutting edgeresearch, and the latest Parkinson’s topics to foster new ideas andcollaboration among Parkinson’s clinicians, scientists, andresearchers.
• Parkinson’sAssociation of San Diego Step by Step 5K Walk on April 7 includedACADIA employees helping raise funds to support critical resources forthe estimated 60,000 people affected by Parkinson’s disease in SanDiego County where ACADIA is headquartered.

"Moving Day walks are a critical component of the Parkinson’sFoundation’s efforts to raise money and help improve life for peopleaffected by Parkinson’s disease," said John Lehr, President and ChiefExecutive Officer of the Parkinson’s Foundation. "We appreciate ACADIA’ssupport to help make events including Moving Day possible. Funds raisedthrough Moving Day help us deliver quality care, fund cutting-edgeresearch, and provide free resources for people living with Parkinson’sand their families. Since 2011, Moving Day events across the countryhave gathered more than 130,000 participants and raised nearly $22million to improve care and advance research toward a cure.”

About Parkinson’s Disease and Parkinson’s Disease Psychosis
Parkinson’sdisease is a progressive nervous system disorder. About one millionpeople in the United States and from four to six million peopleworldwide suffer from Parkinson’s disease. The signs and symptoms ofParkinson’s can vary from person to person but generally fall into twotypes: motor and non-motor symptoms. Hallucinations (seeing, hearing, orexperiencing things that others don’t) and delusions (believing thingsthat aren’t true) are non-motor symptoms of Parkinson’s disease.Together they are known as PDP and may affect around half of peopleliving with PD over the course of their disease. People who developnon-motor symptoms of PD like hallucinations or delusions often have todeal with a broader set of challenges that can be more troublesome thanmotor symptoms in terms of quality of life. These non-motor symptoms maycome with increased caregiver distress and burden and nursing homeplacement. More information about PDP is available at: www.Moretoparkinsons.com.

About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed the first and only medicine approved forthe treatment of hallucinations and delusions associated withParkinson’s disease psychosis. In addition, ACADIA has ongoing clinicaldevelopment efforts in additional areas with significant unmet need,including dementia-related psychosis, schizophrenia inadequate response,schizophrenia-negative symptoms, major depressive disorder, and Rettsyndrome. This press release and further information about ACADIA can befound at: www.acadia-pharm.com.

Important Safety Information and Indication forNUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITHDEMENTIA-RELATED PSYCHOSIS

• Elderly patients with dementia-related psychosis treated withantipsychotic drugs are at an increased risk of death.
• NUPLAZID is not approved for the treatment of patients withdementia-related psychosis unrelated to the hallucinations anddelusions associated with Parkinson’s disease psychosis.

Contraindication: NUPLAZID is contraindicated in patients with ahistory of a hypersensitivity reaction to pimavanserin or any of itscomponents. Rash, urticaria, and reactions consistent with angioedema(e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea)have been reported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. Theuse of NUPLAZID should be avoided in patients with known QT prolongationor in combination with other drugs known to prolong QT intervalincluding Class 1A antiarrhythmics or Class 3 antiarrhythmics, certainantipsychotic medications, and certain antibiotics. NUPLAZID should alsobe avoided in patients with a history of cardiac arrhythmias, as well asother circumstances that may increase the risk of the occurrence oftorsade de pointes and/or sudden death, including symptomaticbradycardia, hypokalemia or hypomagnesemia, and presence of congenitalprolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% forNUPLAZID and greater than placebo) were peripheral edema (7% vs 2%),nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors(e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID doseto 10 mg taken orally as one tablet once daily. Coadministration withstrong CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patientsfor reduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established inpediatric patients.

Dosage and Administration: Recommended dose: 34 mg taken orallyonce daily, without titration.

Indication: NUPLAZID is an atypical antipsychotic indicated forthe treatment of hallucinations and delusions associated withParkinson’s disease psychosis.

You are encouraged to report negative side effects of prescription drugsto the FDA. Visit www.fda.gov/medwatch,or call 1-800-FDA-1088. You can also call ACADIA Pharmaceuticals Inc. at1-844-4ACADIA (1-844-422-2342).

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please see the full Prescribing Information including Boxed WARNINGfor NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:

ACADIA Pharmaceuticals Inc.
MarkJohnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Media Contact:

ACADIA Pharmaceuticals Inc.
MaurissaMessier
(858) 768-6068
media@acadia-pharm.com